Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5730378 | The Journal of Sexual Medicine | 2017 | 11 Pages |
Abstract
The VIVEVE I trial is the first randomized, controlled, blinded, clinical study of RFc for the treatment of vaginal laxity. A single treatment of RFc therapy was found to be safe and associated with both improved vaginal laxity and improved sexual function. The results from this trial support the use of a novel non-surgical therapy for vaginal laxity, a prevalent and undertreated condition.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Urology
Authors
Michael MD, Christopher G. PhD, Bruce B. MD, PhD, FRCS(C), Leonard PhD, Scott MPH, Ashley BSc, Deborah PhD,